These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

68 related articles for article (PubMed ID: 6811918)

  • 21. The effects of racemic D,L-methadone and L-methadone in substituted patients--a randomized controlled study.
    Verthein U; Ullmann R; Lachmann A; Düring A; Koch B; Meyer-Thompson HG; Schmidt R; Reimer J; Haasen C
    Drug Alcohol Depend; 2005 Nov; 80(2):267-71. PubMed ID: 15916866
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Low efficacy of non-opioid drugs in opioid withdrawal symptoms.
    Hermann D; Klages E; Welzel H; Mann K; Croissant B
    Addict Biol; 2005 Jun; 10(2):165-9. PubMed ID: 16191669
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Influence of the dose on the severity of opiate withdrawal symptoms during methadone detoxification.
    Glasper A; Gossop M; de Wet C; Reed L; Bearn J
    Pharmacology; 2008; 81(2):92-6. PubMed ID: 17952010
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In-patient detoxification procedures, treatment retention, and post-treatment opiate use: comparison of lofexidine + naloxone, lofexidine + placebo, and methadone.
    McCambridge J; Gossop M; Beswick T; Best D; Bearn J; Rees S; Strang J
    Drug Alcohol Depend; 2007 Apr; 88(1):91-5. PubMed ID: 17064857
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The effect of mianserin add-on, on the intensity of opioid withdrawal symptoms during detoxification program--a randomized, double blind, placebo controlled, prospective study.
    Herman I; Shamir D; Bar-Hamburger R; Pick CG; Schreiber S
    Addict Behav; 2005 Jul; 30(6):1154-67. PubMed ID: 15925125
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Naltrexone-assisted rapid methadone discontinuation: a pilot study.
    Camarasa X; Khazaal Y; Besson J; Zullino DF
    Eur Addict Res; 2007; 13(1):20-4. PubMed ID: 17172775
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of methadone dosage on clonidine detoxification efficacy.
    Gold MS; Pottash AL; Sweeney DR; Kleber HD
    Am J Psychiatry; 1980 Mar; 137(3):375-6. PubMed ID: 7356071
    [No Abstract]   [Full Text] [Related]  

  • 28. Patterns of symptom complaints in methadone maintenance patients.
    Dyer KR; White JM
    Addiction; 1997 Nov; 92(11):1445-55. PubMed ID: 9519488
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Baclofen for outpatient treatment of alcohol withdrawal syndrome.
    Addolorato G; Leggio L; Abenavoli L; Caputo F; Gasbarrini G
    J Fam Pract; 2005 Jan; 54(1):24. PubMed ID: 15623403
    [No Abstract]   [Full Text] [Related]  

  • 30. Opioid plasma concentrations in methadone-and buprenorphine-maintained patients.
    Jagsch R; Gombas W; Schindler SD; Eder H; Moody DE; Fischer G
    Addict Biol; 2005 Dec; 10(4):365-71. PubMed ID: 16318959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Craving despite extremely high methadone dosage.
    de Vos JW; Ufkes JG; van Brussel GH; van den Brink W
    Drug Alcohol Depend; 1996 Mar; 40(3):181-4. PubMed ID: 8861396
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Methadone-induced endorphin dysfunction in addicts.
    Gold MS; Pottash AC; Extein I; Martin D; Kleber HD
    NIDA Res Monogr; 1982 Apr; 41():476-82. PubMed ID: 6289119
    [No Abstract]   [Full Text] [Related]  

  • 33. Administration of meptazinol to opiate-dependent patients.
    Evans M; Robson PJ; Chadd MA; Evans CM; Fry DM
    Postgrad Med J; 1983; 59 Suppl 1():78-84. PubMed ID: 6835896
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Effect of diclofenac on the opiate withdrawal syndrome].
    Gerra G; Ceresini G; Rastelli G; Butturini L; Vescovi PP
    G Clin Med; 1985; 66(11-12):459-65. PubMed ID: 3835090
    [No Abstract]   [Full Text] [Related]  

  • 35. Medical mismanagement in public methadone programs.
    Addiss SS; Horosko S
    Conn Med; 1994 Mar; 58(3):173-4. PubMed ID: 8039382
    [No Abstract]   [Full Text] [Related]  

  • 36. Acetyl-L-carnitine in the management of pain during methadone withdrawal syndrome.
    Janiri L; Martinotti G; Tonioni F; Ghelardini C; Nicolai R; Galeotti N; Mosconi L; Calvani M; Bartolini A; Iannoni E
    Clin Neuropharmacol; 2009; 32(1):35-40. PubMed ID: 18978503
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Absence of opioid withdrawal symptoms in patients receiving methadone and the protease inhibitor lopinavir-ritonavir.
    Clarke S; Mulcahy F; Bergin C; Reynolds H; Boyle N; Barry M; Back DJ
    Clin Infect Dis; 2002 Apr; 34(8):1143-5. PubMed ID: 11915005
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Early recurrence of withdrawal symptoms under phenytoin and chronic alcohol use.
    Knoll B; Haefeli WE; Ladewig D; Stohler R
    Pharmacopsychiatry; 1997 Mar; 30(2):72-3. PubMed ID: 9131728
    [No Abstract]   [Full Text] [Related]  

  • 39. Baclofen in cannabis dependence syndrome.
    Nanjayya SB; Shivappa M; Chand PK; Murthy P; Benegal V
    Biol Psychiatry; 2010 Aug; 68(3):e9-10. PubMed ID: 20494335
    [No Abstract]   [Full Text] [Related]  

  • 40. [Withdrawal of drug addicts from opiates using Limoge-type electrotherapy. Evaluation of 400 treatments].
    Bourgeois M; Tignol J; Daubech JF; Daulouede JP; Allison W; Allison F; de Saint-Affrique H; Meggle D
    Ann Med Psychol (Paris); 1982 May; 140(5):540-6. PubMed ID: 6758642
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.